Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 16, 2024
Data Byte
EMA’s CHMP finds path to Leqembi nod, backs three other new drugs
Eleven label expansions also among committee’s November recommendations
BioCentury | Oct 31, 2024
Emerging Company Profile
IHP: Creating an EpiPen for sickle cell disease
Company aims to keep patients out of hospital with a dual-mechanism rescue treatment to prevent vaso-occlusive crises
BioCentury | Jul 17, 2024
Data Byte
FDA’s five NME approvals in June bring 1H24 total to 21
Ipsen’s Iqirvo, Geron’s Rytelo among June highlights
BioCentury | Mar 23, 2024
Data Byte
EMA’s CHMP backs approval of Novartis’ complement drug
March decisions also include label extensions for UCB’s Bimzelx and Astellas’ Xtandi. Takeda pulls an application for Adcetris
BioCentury | Mar 14, 2024
Deals
AstraZeneca’s Amolyt takeout among largest ever for a French biotech
Deal for $800M up front adds hypoparathyroidism asset, now in Phase III, to AZ’s Alexion portfolio; shareholders could receive $250M milestone
BioCentury | Nov 14, 2023
Data Byte
The six new drugs FDA approved in October
Autoimmune disease therapies accounted for four of FDA’s six NME approvals last month
BioCentury | Oct 19, 2023
Regulation
Oct. 18 Quick Takes: FDA approves UCB’s Bimzelx and Zilbrysq
Plus: After appeal, Ardelyx wins approval of kidney therapy, and updates from Mablink, Actym, Syncona, CDER and more
BioCentury | Sep 20, 2023
Data Byte
Immunology companies acquired by pharmas in 2020-23
At least 13 immunology-focused biotechs have been acquired for ≥$1B since start of 2020, with three of the deals announced this year
BioCentury | Sep 6, 2023
Finance
Sept. 6 Quick Takes: Patient Square again fuels Apollo’s mission in $226.5M series C
Plus: Astellas drops IRA lawsuit after CMS passes on Xtandi and updates on Ultomiris, Rybrevant, exo-cel, Tentarix, Rejuvenation, and more
BioCentury | Sep 1, 2023
Finance
The Cystic Fibrosis Powerhouse: Vertex
Back to School 2023 case study: How Vertex kept raising the bar to dominate a therapeutic space
Items per page:
1 - 10 of 574